Clinically recommended doses and the severity of side effects correlate with the PARP inhibitor trapping potency; talazoparib as the strongest PARP trapper has the lowest recommended dose and shows the highest occurrence of anemia (de Bono et al. 2017; Litton et al. 2018; Pilié et al. 2019a). The gene discussed is PARP1; the disease is anemia.